Accelevir Diagnostics Scientific Team · Published September 2026 · accelevirdx.com
Your next development decision depends on more than a convincing knockdown percentage. It depends on whether that percentage reflects the biology.
When an RNA-targeting therapeutic produces a strong knockdown result, the next steps can move quickly: select the lead, optimize the dose, advance the study.
But what if part of that apparent activity comes from interference in the measurement itself?
A new Nature Biotechnology study from Johns Hopkins researchers Leslie Watkins, Alan Zhu, and Bin Wu shows how real that risk is—and reinforces why Accelevir approaches challenging bioanalysis through custom assay development, controlled sample workflows, and complementary analytical methods.
Before you advance on a knockdown result, make sure your assay can support the decision.
What the study found
The most striking result: catalytically inactive (“dead”) CRISPR enzymes—which cannot cut RNA and produced no knockdown at the protein level—still appeared to knock down their targets by RT-qPCR. For one target (XIST), an amplicon spanning the guide site reported roughly 90% knockdown for both the active and the dead enzyme. An amplicon downstream of the guide site reported about 35% for the active enzyme and 14% for the dead one.
The cause: guide RNAs co-purify with cellular RNA during extraction and interfere primarily with reverse transcription. That lowers the measured signal and makes knockdown look greater than it is.
Where you measure matters. Amplicons spanning the guide-binding site, or just upstream of it, were affected. The upstream effect faded with distance and disappeared beyond roughly 500 nucleotides, while downstream amplicons were unaffected. The artifact appeared in all three RNA-targeting CRISPR systems tested (Csm, PspCas13b, and CasRx).
The authors describe two ways to avoid it: pair spanning amplicons with a highly processive, strand-displacing reverse transcriptase, or use conventional reverse transcription with downstream amplicons. They also recommend orthogonal measurements whenever possible, and note that phenol–chloroform extraction and oligo(dT) priming could make the problem worse.
The study focused on CRISPR, but the authors point out that related artifacts may also affect siRNA, shRNA, and ASO knockdown measurements.
For development teams, this raises a practical question:
How much confidence should you place in a result that has only been measured one way?
Accelevir’s approach starts with the measurement challenge
Accelevir’s scientific roots are in measuring ultra-rare biological events—where sample quality, assay specificity, and interpretation are inseparable.
Our experience includes low-abundance viral targets, persistent HIV reservoirs, and complex molecular measurements. Our capabilities combine custom molecular assay development with controlled workflows and cross-platform confirmation—the same elements this paper shows are needed to trust a knockdown result.
For CRISPR and siRNA and ASO programs, applying that expertise means asking the right questions before accepting the readout.
1. Design the assay around the therapeutic mechanism
A standard assay may detect your target without answering your development question.
Where does the guide or oligonucleotide bind? Is the amplicon upstream of, across, or downstream of that site? Which reverse transcriptase and priming strategy are used? Could the assay detect residual fragments?
Accelevir develops and optimizes custom molecular assays, with qualification or validation matched to the intended application. That enables a program-specific discussion about what must be measured, what could interfere, and what evidence is needed to interpret the result.
The goal is a measurement strategy built around your target, sample matrix, and decision.
2. Evaluate the workflow—not just the instrument
An advanced platform cannot compensate for every bias introduced before the sample reaches it.
Accelevir’s published IPDA workflows emphasize controlled sample handling, established procedures, and quality management. That experience provides a foundation for evaluating the steps that influence molecular measurements, from sample processing through analysis.
For an RNA knockdown assay, an interference assessment can be scoped to examine the extraction method (including small-RNA carryover), reverse-transcription enzyme and priming, amplicon placement, and appropriate controls.
The practical objective: identify whether a change in signal reflects a change in target abundance.
3. Use complementary evidence that challenges the result
Repeating a measurement can demonstrate precision. Independent evidence helps establish whether the interpretation is sound.
In the study itself, the decisive evidence came from protein: flow cytometry showed that the dead enzymes did not reduce protein levels, which exposed the RNA-level artifact.
Accelevir offers qPCR and digital PCR, sequencing, and flow cytometry, alongside cross-platform assay confirmation. The appropriate combination depends on the biological question and the potential source of bias.
Importantly, switching from qPCR to digital PCR does not automatically resolve an artifact introduced during reverse transcription. A downstream measurement can inherit an upstream bias. The authors raise the same caution for RNA sequencing when cDNA is synthesized without prior RNA fragmentation.
A useful confirmation strategy must therefore test the suspected failure mechanism. Depending on the target, that may include an independently designed RNA measurement or a suitable protein or functional endpoint.
Build confidence before the next milestone
You may be selecting a lead, investigating inconsistent results, or preparing to expand a study. Each is an opportunity to ask whether your analytical strategy is strong enough for the decision ahead.
Accelevir can help scope custom assay development, optimization, and fit-for-purpose qualification or validation around your program’s needs.
Planning an RNA-targeting study—or questioning an existing knockdown result?
Start with a non-confidential summary of your target, platform, sample type, and the decision your data need to support. Our team can discuss your current approach and identify where additional assay development or complementary measurements may be valuable.
Start your project or email info@accelevir.com to discuss your knockdown assay.
Reference: Watkins, L., Zhu, A. & Wu, B. “A pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR.” Nature Biotechnology (published September 1, 2026; open access). https://doi.org/10.1038/s41587-026-03291-1. Accelevir was not involved in this research.